Table 1.
Demographic and clinical data at the first meropenem therapeutic drug monitoring.
| Variable | n (%) or Median (IQR) |
|---|---|
| Sex (male/female) | 92/52 (63.9/36.1) |
| Age (years) | 72 (60–79) |
| Weight (kg) | 75 (65–85) |
| Height (cm) | 170 (164–178) |
| BMI (kg/m2) | 25 (23–28) |
| Serum total protein (g/L) | 56.0 (51.0–61.2) |
| Serum albumin (g/L) | 28.5 (24.0–32.4) |
| Alanine aminotransferase (UI) | 23.0 (13.2–42.5) |
| Serum creatinine (mg/dL) | 0.90 (0.63–1.42) |
| Patients with eCLCr 1 < 10 mL/min | 0 (0) |
| eCLCr 1 in < 10 mL/min group | - |
| Patients with eCLCr 1 10–25 mL/min | 14 (10.1) |
| eCLCr 1 in 10–25 mL/min group | 16.25 (14.15–19.43) |
| Patients with eCLCr 1 26–50 mL/min | 30 (21.6) |
| eCLCr 1 in 26–50 mL/min group | 30.15 (33.05–45.75) |
| Patients with eCLCr 1 50–120 mL/min | 62 (44.6) |
| eCLCr 1 in 50–120 mL/min group | 81.05 (65.73–98.63) |
| Patients with eCLCr 1 >120 mL/min | 33 (23.7) |
| eCLCr 1 in >120 mL/min group | 159.10 (136.60–197.30) |
| C-reactive protein (mg/L) | 58.3 (22.1–123.7) |
| Time between initiation therapy with meropenem and first TDM (hours) | 96 (72–120) |
1 eCLCr: estimated clearance of creatinine according to the Cockroft–Gault formula.